Solid Tumor Market By Type (Benign, Malignant, Others), By Drug (Avastin, Afinitor, Others) Regional Analysis & Forecast – 2026
- OI-86 |
- Published date: Mar, 2019 |
- Oncology/Hematology |
- Pages
Solid tumors are considered as the abnormal mass of tissue without containing cysts or liquid. Solid tumors are composed of heterogeneous populations of normal and cancerous cells. Solid tumors are classified into two types in medical terms, like benign (non-cancerous) and malignant (cancerous) in nature. Solid tumors mainly comprise of lymphomas, carcinomas, sarcomas, and melanomas; whereas, all forms of leukemias usually do not cause solid tumor formation. Solid tumor drugs are pharmaceuticals that are specifically used to treat various cancers, including breast cancer, lung cancer, prostate cancer, cervical cancer, colorectal cancer, and others. Most of the solid tumors are treated by radiotherapy, chemotherapy and/or surgery. Chemotherapy is often applied along with other modes of solid tumor treatment of radiation and/or surgery.
Market Overview
In 2018, the global Solid Tumor Testing market size was US$ XX million, and it is expected to reach US$ XX million by the end of 2025, with a CAGR of xx% during 2019-2025. The growing incidence of cancer is going to drive the solid tumor market. The other factors including the increasing demand for POC testing, new product approvals in pancreatic, ovarian, and prostate cancers, and the rise in molecular testing are driving the solid tumor market. In addition, some other factors fuelling the growth of solid tumors market include unmet demand for cancer treatment and the rise in investment in the research and development of cancer drugs.
The United States patent for one of the basic compound of Gleevec was expired in July 2015 that resulted in one of Sun Pharmaceutical Industries subsidiaries allowed to sell a generic version of the drug in America from February 2016. Already Gleevec has been launched in the United States, while the European launch was in December 2016. These generic medicines are thus hindering the growth of the solid tumor market. The other factors including expensive procedures and regulatory complications, the high cost of cancer therapy, and growing drug patent cliff are also hindering the growth of the market.
Further, the emerging trend of biosimilars contributes to the growth of solid tumors market due to the presence of low cost and possessing similarity to the originator compound. For example, some of the biologics available for solid tumors treatment are Herceptin, Avastin, MabThera, and Erbitux. The advantages of these biosimilars to overcome the limitations of generic drugs in the treatments is expected to propel the growth of solid tumors market.
Key Developments
- In Feb 2019, Pfizer announced that the European Commission had approved its Avastin® (bevacizumab) biosimilar ZIRABEV™ for the treatment of metastatic breast cancer, metastatic carcinoma of the colon or rectum, advanced and/or metastatic renal cell cancer, NSCLC, and persistent, recurrent or metastatic carcinoma of the cervix.
- In Feb 2019, Roche announced that the US FDA had approved Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk), for subcutaneous injection for the treatment of HER2-positive breast cancer.
Segmentation
The report segments the Solid Tumor Market on the basis of drug, types, and the region as follows:
On the basis of drug: Avastin (bevacizumab), Afinitor (everolimus), JSutent (sunitinib), Tarceva (erlotinib), evtana (cabazitaxel), Taxotere (docetaxel), Zytiga (abiraterone acetate), Cisplatin, Doxorubicin, Carboplatin, Gemcitabine, and Paclitaxel.
On the basis of Type: Benign (non-cancerous) and Malignant (cancerous).
On the basis regions: North America, Europe, Asia Pacific, Central & South America, and Middle East & Africa.
The United States solid tumor market held the largest market share in the North American region due to the existence of a high-quality healthcare system and modern medical technology in the country. North America was found to be followed by Europe and Asia-Pacific as the second and third largest market for solid tumor market.
The major players include Abbott Laboratories, Inc., Amgen, Inc., AstraZeneca PLC, Baxter International, Inc., Biogen, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F.F. Hoffmann-La Roche AG, and GlaxoSmithKline PLC, among others.
Report Description: The report covers in-depth analysis of Solid Tumor Market. The report assesses the market products pipeline by stage of development (early development, pre-clinical, clinical and in approval), by application (breast cancer, lung cancer, prostate cancer, cervical cancer, and others). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.
The report includes in-depth company profiles of key players in Solid Tumor Market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments.
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Scope:
- Provides detailed analysis of the market structure along with forecast of the various segments and sub-segments of the Solid Tumor
- Provides a comparative analysis of key marketed products and pipeline market products.
- Provides key information on players involved on the Solid Tumor
- Provides a complete overview of market segments and the regional outlook of Solid Tumor
- Provides in-depth coverage of key news related to Solid Tumor Market, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates
-
Data Collation (Primary & Secondary)
-
In-house Estimation (Based on proprietary databases and Models)
-
Market Triangulation
-
Forecasting
-
Market-related information is assembled from both primary and secondary sources.
-
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
-
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
-
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.
